Airways delivery of rifampicin microparticles for the treatment of tuberculosis | Zendy

Sandra OrozcoSuárez | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Airways delivery of rifampicin microparticles for the treatment of tuberculosis

Author(s) -

Sandra OrozcoSuárez

Publication year - 2001

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/48.3.431

Subject(s) - plga , rifampicin , pharmacology , excipient , medicine , mycobacterium tuberculosis , tuberculosis , microbiology and biotechnology , lactose , lung , chemistry , pathology , biology , in vitro , food science , biochemistry

A Mycobacterium tuberculosis (H37Rv)-infected guinea pig model was used to screen for targeted delivery to the lungs by insufflation (with lactose excipient) or nebulization, of either rifampicin alone, rifampicin within poly(lactide-co-glycolide) microspheres (R-PLGA) or polymer microparticles alone (PLGA). Animals treated with single and double doses of R-PLGA microspheres exhibited significantly reduced numbers of viable bacteria, inflammation and lung damage compared with lactose-, PLGA- or rifampicin-treated animals 28 days post-infection (P < 0.05). Two doses of R-PLGA resulted in reduced splenic enlargement. These studies support the potential of R-PLGA delivered to the lung to treat pulmonary tuberculosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research